Follow
Joke Bilcke
Joke Bilcke
Center for Health Economics Research and Modeling of Infectious Diseases, University of Antwerp
Verified email at uantwerp.be
Title
Cited by
Cited by
Year
Rotavirus disease and vaccination: impact on genotype diversity
J Matthijnssens, J Bilcke, M Ciarlet, V Martella, K Bányai, M Rahman, ...
Future microbiology 4 (10), 1303-1316, 2009
3142009
Rotavirus disease and vaccination: impact on genotype diversity
J Matthijnssens, J Bilcke, M Ciarlet, V Martella, K Bányai, M Rahman, ...
Future microbiology 4 (10), 1303-1316, 2009
3142009
Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide
J Bilcke, P Beutels, M Brisson, M Jit
Medical Decision Making 31 (4), 675-692, 2011
1572011
Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015)
L Willem, F Verelst, J Bilcke, N Hens, P Beutels
BMC infectious diseases 17 (1), 1-16, 2017
1272017
Biomass production efficiency controlled by management in temperate and boreal ecosystems
M Campioli, S Vicca, S Luyssaert, J Bilcke, E Ceschia, FS Chapin Iii, ...
Nature Geoscience 8 (11), 843-846, 2015
1132015
The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe
M Jit, J Bilcke, MJJ Mangen, H Salo, H Melliez, WJ Edmunds, Y Yazdan, ...
Vaccine 27 (44), 6121-6128, 2009
1022009
Detection of human papillomavirus DNA in urine. A review of the literature
A Vorsters, I Micalessi, J Bilcke, M Ieven, J Bogers, P Van Damme
European journal of clinical microbiology & infectious diseases 31 (5), 627-640, 2012
982012
Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community
B Ultsch, O Damm, P Beutels, J Bilcke, B Brüggenjürgen, A Gerber-Grote, ...
Pharmacoeconomics 34 (3), 227-244, 2016
972016
The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom
AJ Van Hoek, A Melegaro, N Gay, J Bilcke, WJ Edmunds
Vaccine 30 (6), 1225-1234, 2012
772012
Reviewing the cost effectiveness of rotavirus vaccination
J Bilcke, P Beutels
Pharmacoeconomics 27 (4), 281-297, 2009
642009
Cost-Effectiveness of Rotavirus Vaccination: Exploring Caregiver (s) and``No Medical Care''Disease Impact in Belgium
J Bilcke, P Van Damme, P Beutels
Medical Decision Making 29 (1), 33-50, 2009
612009
The health and economic burden of chickenpox and herpes zoster in Belgium
J Bilcke, B Ogunjimi, C Marais, F De Smet, M Callens, K Callaert, ...
Epidemiology & Infection 140 (11), 2096-2109, 2012
562012
Estimating the incidence of symptomatic rotavirus infections: a systematic review and meta-analysis
J Bilcke, P Van Damme, M Van Ranst, N Hens, M Aerts, P Beutels
PloS one 4 (6), e6060, 2009
552009
Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
J Bilcke, A Jan van Hoek, P Beutels
Human vaccines & immunotherapeutics 9 (4), 812-822, 2013
522013
Influenza-like-illness and clinically diagnosed flu: disease burden, costs and quality of life for patients seeking ambulatory care or no professional care at all
J Bilcke, S Coenen, P Beutels
PloS one 9 (7), e102634, 2014
492014
Did large-scale vaccination drive changes in the circulating rotavirus population in Belgium?
VE Pitzer, J Bilcke, E Heylen, FW Crawford, M Callens, F De Smet, ...
Scientific reports 5 (1), 1-14, 2015
482015
Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low-and middle-income settings
M Antillón, J Bilcke, AD Paltiel, VE Pitzer
Vaccine 35 (27), 3506-3514, 2017
452017
Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014
M Sabbe, N Berger, A Blommaert, B Ogunjimi, T Grammens, M Callens, ...
Eurosurveillance 21 (27), 30273, 2016
442016
An update to “The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe”
M Jit, MJJ Mangen, H Melliez, Y Yazdanpanah, J Bilcke, H Salo, ...
Vaccine 28 (47), 7457-7459, 2010
442010
Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
J Bilcke, M Antillón, Z Pieters, E Kuylen, L Abboud, KM Neuzil, AJ Pollard, ...
The Lancet Infectious Diseases 19 (7), 728-739, 2019
422019
The system can't perform the operation now. Try again later.
Articles 1–20